Back to Search
DAVID GOLDSTEIN, M.D.
M.D.
Physical Medicine & Rehabilitation Physician
NPI: 1750474433Individual
Specialties, Licenses & Credentials
Physical Medicine & Rehabilitation PhysicianPrimary
Physical Medicine & Rehabilitation
Code: 208100000X
MD033446E(PA)
Research & Publications (20)
Outcomes following reirradiation of patients with head and neck cancer.
PMID 18286493·Head Neck·2008
8-other
High-throughput kinase profiling as a platform for drug discovery.
PMID 18404149·Nat Rev Drug Discov·2008
6-review
Outposts of science; the knowledge trade and the expansion of scientific community in post-Civil War America.
PMID 18959194·Isis·2008
8-other
Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants.
PMID 17923537·Arch Ophthalmol·2007
8-other
Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer.
PMID 17653074·Br J Cancer·2007
3-trial
Influence of oil droplet surface charge on the performance of antibody--emulsion conjugates.
PMID 17011740·Biomed Pharmacother·2007
8-other
Wait times in the diagnosis and treatment of head and neck cancer: comparison between wait times in 1995 and 2005--a prospective study.
PMID 18076843·J Otolaryngol·2007
4-observational
Anti-HER2 cationic immunoemulsion as a potential targeted drug delivery system for the treatment of prostate cancer.
PMID 17210707·Cancer Res·2007
7-preclinical
Duloxetine in the treatment of major depressive disorder.
PMID 19300553·Neuropsychiatr Dis Treat·2007
8-other
Health-related quality of life profiles based on survivorship status for head and neck cancer patients.
PMID 17163462·Head Neck·2007
8-other
The identity of innate immune activators in organ transplantation: origins from within or exterior to the host?
PMID 17524077·Am J Transplant·2007
8-other
Fatigue states after cancer treatment occur both in association with, and independent of, mood disorder: a longitudinal study.
PMID 17026776·BMC Cancer·2006
8-other
Discovery of S-[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy)phenyl]methanone (RO3201195), an orally bioavailable and highly selective inhibitor of p38 MAP kinase.
PMID 16509574·J Med Chem·2006
7-preclinical
Pathway to the clinic: inhibition of P38 MAP kinase. A review of ten chemotypes selected for development.
PMID 16178744·Curr Top Med Chem·2005
4-observational
The design and evaluation of a novel targeted drug delivery system using cationic emulsion-antibody conjugates.
PMID 16226821·J Control Release·2005
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 2500 BROOKTREE ROAD, SUITE 300
WEXFORD, PA 15090 - Phone
- (724) 934-7780
Quick Facts
- NPI
- 1750474433
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile